Intensive Safety Monitoring of Rituximab (Biosimilar Novex® and the Innovator) in Pediatric Patients With Complex Diseases

Intensive Safety Monitoring of Rituximab (Biosimilar Novex® and the Innovator) in Pediatric Patients With Complex Diseases

Although rituximab is widely used off-label for complex pediatric diseases, safety reports are limited. We aimed to report evidence of its use in clinical practice, to describe the incidence of adverse drug reactions (ADR) to rituximab biosimilar Novex® and innovator, and to identify risk factors fo...

Full description

Bibliographic Details
Main Authors: Natalia Riva, Manuel Molina, Berta L. Cornaló, María V. Salvador, Andrea Savransky, Silvia Tenembaum, María M. Katsicas, Marta Monteverde, Paulo Cáceres Guido, Marcela Rousseau, Raquel Staciuk, Agustín González Correas, Pedro Zubizarreta, Oscar Imventarza, Eduardo Lagomarsino, Eduardo Spitzer, Marcelo Tinelli, Paula Schaiquevich
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Pharmacology
Subjects:
Rituximab
Biosimilar Pharmaceuticals
Monoclonal Antibody
Pediatric
Adverse Drug Reactions
Hypersensitivity
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.785770/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.785770/full

Similar Items